Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

26 Oct 2006 17:29

GW Pharmaceuticals PLC26 October 2006 BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: GW PHARMACEUTICALS PLC 2. NAME OF SCHEME: GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME 3. PERIOD OF RETURN: FROM: 27 APRIL 2006 TO: 25 OCTOBER 2006 4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUEDUNDER SCHEME AT END OF THE LAST PERIOD: 150,750 ORDINARY SHARES OF 0.1P EACH 5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD: NIL ORDINARY SHARES OF 0.1P EACH 6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD: 150,750 ORDINARY SHARES OF 0.1P EACH 7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYLISTED AND THE DATE OF ADMISSION: 507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003 PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERFOR US TO UPDATE OUR RECORDS. 120,076,035 ORDINARY SHARES OF 0.1P EACH BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: GW PHARMACEUTICALS PLC 2. NAME OF SCHEME: GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME 3. PERIOD OF RETURN: FROM: 27 APRIL 2006 TO: 25 OCTOBER 2006 4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUEDUNDER SCHEME AT END OF THE LAST PERIOD: 604,962 ORDINARY SHARES OF 0.1P EACH 5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD: NIL ORDINARY SHARES OF 0.1P EACH 6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD: 604,962 ORDINARY SHARES OF 0.1P EACH 7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYLISTED AND THE DATE OF ADMISSION: 1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003 PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERFOR US TO UPDATE OUR RECORDS. 120,076,035 ORDINARY SHARES OF 0.1P EACH BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: GW PHARMACEUTICALS PLC 2. NAME OF SCHEME: GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001 3. PERIOD OF RETURN: FROM: 27 APRIL 2006 TO: 25 OCTOBER 2006 4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUEDUNDER SCHEME AT END OF THE LAST PERIOD: 435,358 ORDINARY SHARES OF 0.1P EACH 5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD: NIL ORDINARY SHARES OF 0.1P EACH 6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD: 435,358 ORDINARY SHARES OF 0.1P EACH 7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYLISTED AND THE DATE OF ADMISSION: 516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004 PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERFOR US TO UPDATE OUR RECORDS. 120,076,035 ORDINARY SHARES OF 0.1P EACH BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: GW PHARMACEUTICALS PLC 2. NAME OF SCHEME: GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001 3. PERIOD OF RETURN: FROM: 27 APRIL 2006 TO: 25 OCTOBER 2006 4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUEDUNDER SCHEME AT END OF THE LAST PERIOD: 1,276,492 ORDINARY SHARES OF 0.1P EACH 5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD: NIL ORDINARY SHARES OF 0.1P EACH 6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD: 1,276,492 ORDINARY SHARES OF 0.1P EACH 7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYLISTED AND THE DATE OF ADMISSION: 1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004 PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERFOR US TO UPDATE OUR RECORDS. 120,076,035 ORDINARY SHARES OF 0.1P EACHFor further information, please contact: Jonathan Laughton, GW Pharmaceuticals plc Telephone: 01980 557000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Dec 20104:15 pmRNSDirector/PDMR Shareholding
9th Dec 20102:39 pmRNSPublication of Annual Report
8th Dec 20103:52 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSChange of Adviser
29th Nov 20104:31 pmRNSDirector/PDMR Shareholding
23rd Nov 20107:01 amRNSSativex Enters Phase III Cancer Pain Programme
23rd Nov 20107:00 amRNSFinal Results
19th Nov 201010:10 amRNSUpdate on Nomad and Broker Position
3rd Nov 20107:00 amRNSSativex Approved in New Zealand for MS Spasticity
21st Oct 201011:30 amRNSNotice of Results
21st Oct 201011:30 amRNSNotice of Results
14th Oct 20109:30 amRNSResearch Update
13th Oct 201012:12 pmRNSHolding(s) in Company
30th Sep 20107:03 amRNSGW Starts Phase IIa Study Programme
22nd Sep 20107:00 amRNSSativex Study Results Published in Peer Journal
16th Sep 20109:29 amRNSHolding(s) in Company
16th Sep 20109:28 amRNSHolding(s) in Company
14th Sep 20105:16 pmRNSDirector/PDMR Shareholding
9th Sep 201011:51 amRNSDirector/PDMR Shareholding
31st Aug 20107:00 amRNSHealth Canada Grants Full Approval of Sativex
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
28th Jul 20107:00 amRNSSativex receives regulatory authorisation in Spain
27th Jul 20107:00 amRNSDirectorate Change
23rd Jul 20105:10 pmRNSDirector/PDMR Shareholding
19th Jul 20103:33 pmRNSDirector/PDMR Shareholding
5th Jul 20105:35 pmRNSDirector/PDMR Shareholding
2nd Jul 201010:03 amRNSResponse to Media Comment
30th Jun 20107:00 amRNSGlobal Cannabinoid Research Collaboration Extended
22nd Jun 201011:23 amRNSGW Pharma to present at Piper Jaffray Conference
21st Jun 20107:00 amRNSUK Launch of First Prescription Cannabis-Medicine
18th Jun 20102:33 pmRNSProduct Update
11th Jun 20103:36 pmRNSDirector/PDMR Shareholding
20th May 20107:00 amRNSInterim Results
11th May 20104:21 pmRNSNotice of Results
28th Apr 20104:40 pmRNSSecond Price Monitoring Extn
28th Apr 20104:35 pmRNSPrice Monitoring Extension
31st Mar 20105:28 pmRNSTotal Voting Rights
25th Mar 20104:07 pmRNSDirector/PDMR Shareholding
24th Mar 20105:21 pmRNSHolding(s) in Company
24th Mar 20102:55 pmRNSResult of AGM
23rd Mar 20103:44 pmRNSHolding(s) in Company
23rd Mar 20103:38 pmRNSHolding(s) in Company
23rd Mar 20107:00 amRNSPositive Data in Sativex Phase IIb Trial
18th Mar 20107:00 amRNSSativex Regulatory Update
18th Jan 20105:27 pmRNSBlock Listing Application
15th Jan 201011:09 amRNSTotal Voting Rights
5th Jan 20104:35 pmRNSPrice Monitoring Extension
11th Dec 20098:57 amRNSDoc re. Annual Report
1st Dec 20097:00 amRNSChange of Adviser
26th Nov 20095:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.